Eli Lilly to buy immuno-oncology firm in $1.6bn deal

11-05-2018

Eli Lilly to buy immuno-oncology firm in $1.6bn deal

designer491 / iStockphoto.com

Eli Lilly has set its sights on Armo BioSciences in a bid to strengthen its immuno-oncology programme.


Eli Lilly, mergers & acquisitions, M&A, Armo Biosciences, immuno-oncology, immunotherapies, oncology

LSIPR